Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Rodgers, Shaefali P ^a,c   Born, Heather A ^a   Das, Pritam ^b   Jankowsky, Joanna L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

Alzheimers disease; Amyloid precursor protein; Amyloid ; APP; Motor hyperactivity; neurodevelopment; Tet off; Tetracycline controllable; Transgenic mouse

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

ADULTHOOD; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BODY WEIGHT; BRAIN DEVELOPMENT; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; FEMALE; GENE OVEREXPRESSION; HYPERACTIVITY; JUVENILE; LOCOMOTION; MALE; MATURATION; MOTOR ACTIVITY; MOUSE; NONHUMAN; ONSET AGE; OPEN FIELD BEHAVIOR; POSTNATAL DEVELOPMENT; TRANSGENE; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; LOCOMOTION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; TRANSGENES;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84862264187     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-28     Document Type: Article

References (60)

1. Alzheimer-type neuropathology in transgenic mice overexpressing V717F -amyloid precursor protein. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. Nature 1995 373 6514 523 527 10.1038/373523a0 7845465
2. Correlative memory deficits, A elevation, and amyloid plaques in transgenic mice. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G, Science 1996 274 5284 99 102 10.1126/science.274.5284.99 8810256
3. Familial Alzheimer's disease-linked presenilin 1 variants elevate A1-42/1-40 ratio in vitro and in vivo. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, et al. Neuron 1996 17 5 1005 1013 10.1016/S0896-6273(00)80230-5 8938131
4. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L, Proc Natl Acad Sci U S A 1999 96 6 3228 3233 10.1073/pnas.96.6.3228 10077666
5. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, et al. J Biol Chem 2001 276 24 21562 21570 10.1074/jbc.M100710200 11279122
6. β-Secretase, APP and A in Alzheimer's disease. Vassar R, Subcell Biochem 2005 38 79 103 10.1007/0-387-23226-5-4 15709474
7. Molecular genetics of Alzheimer's disease. St George-Hyslop PH, Biol Psychiatry 2000 47 3 183 199 10.1016/S0006-3223(99)00301-7 10682216
8. Intraneuronal -amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Espana J, Gimenez-Llort L, Valero J, Minano A, Rabano A, Rodriguez-Alvarez J, LaFerla FM, Saura CA, Biol Psychiatry 2010 67 6 513 521 10.1016/j.biopsych.2009.06.015 19664757
9. Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice. Bedrosian TA, Herring KL, Weil ZM, Nelson RJ, Proc Natl Acad Sci U S A 2011 108 28 11686 11691 10.1073/pnas.1103098108 21709248
10. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, et al. J Biol Chem 1999 274 10 6483 6492 10.1074/jbc.274.10.6483 10037741
11. Expression in brain of amyloid precursor protein mutated in the -secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F, EMBO J 1996 15 6 1265 1274 8635459
12. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Kumar-Singh S, Dewachter I, Moechars D, Lubke U, De Jonghe C, Ceuterick C, Checler F, Naidu A, Cordell B, Cras P, et al. Neurobiol Dis 2000 7 1 9 22 10.1006/nbdi.1999.0272 10671319
13. Activity changes and marked stereotypic behavior precede A pathology in TgCRND8 Alzheimer mice. Ambree O, Touma C, Gortz N, Keyvani K, Paulus W, Palme R, Sachser N, Neurobiol Aging 2006 27 7 955 964 10.1016/j.neurobiolaging.2005. 05.009 15993515
14. Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer's disease. Alexander G, Hanna A, Serna V, Younkin L, Younkin S, Janus C, Behav Brain Res 2011 216 1 77 83 10.1016/j.bbr.2010.07.016 20655336
15. Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. Moechars D, Gilis M, Kuiperi C, Laenen I, Van Leuven F, Neuroreport 1998 9 16 3561 3564 9858360
16. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D, Behav Brain Res 2007 178 1 18 28 10.1016/j.bbr.2006.11.044 17229472
17. Aggressive male APP23 mice modeling behavioral alterations in dementia. Vloeberghs E, Van Dam D, Coen K, Staufenbiel M, De Deyn PP, Behav Neurosci 2006 120 6 1380 1383 17201483
18. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes. Sterniczuk R, Dyck RH, Laferla FM, Antle MC, Brain Res 2010 1348 139 148 20471965
19. Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Bardgett ME, Davis NN, Schultheis PJ, Griffith MS, Neurobiol Learn Mem 2011 95 1 64 72 10.1016/j.nlm.2010.10.008 21073971
20. Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease. Rustay NR, Cronin EA, Curzon P, Markosyan S, Bitner RS, Ellis TA, Waring JF, Decker MW, Rueter LE, Browman KE, Brain Res 2010 1311 136 147 19944081
21. Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease. Walker JM, Fowler SW, Miller DK, Sun AY, Weisman GA, Wood WG, Sun GY, Simonyi A, Schachtman TR, Behav Brain Res 2011 222 1 169 175 10.1016/j.bbr.2011.03.049 21443906
22. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM, Brain Res 2001 891 1-2 42 53 11164808
23. Behavioral disturbances in transgenic mice overexpressing the V717F -amyloid precursor protein. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A, Behav Neurosci 1999 113 5 982 990 10571480
24. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP, Eur J Neurosci 2003 17 2 388 396 10.1046/j.1460-9568.2003.02444.x 12542676
25. Age-dependent phenotypic characteristics of a triple transgenic mouse model of Alzheimer disease. Pietropaolo S, Feldon J, Yee BK, Behav Neurosci 2008 122 4 733 747 18729626
26. Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in PDAPP mice. Huitron-Resendiz S, Sanchez-Alavez M, Gallegos R, Berg G, Crawford E, Giacchino JL, Games D, Henriksen SJ, Criado JR, Brain Res 2002 928 1-2 126 137 11844479
27. Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP, Eur J Neurosci 2004 20 10 2757 2766 10.1111/j.1460-9568.2004.03755.x 15548219
28. Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Wisor JP, Edgar DM, Yesavage J, Ryan HS, McCormick CM, Lapustea N, Murphy GM, Neuroscience 2005 131 2 375 385 10.1016/j.neuroscience.2004.11.018 15708480
29. Characterization of transgene expression and Cre recombinase activity in a panel of Thy-1 promoter-Cre transgenic mice. Campsall KD, Mazerolle CJ, De Repentingy Y, Kothary R, Wallace VA, Developmental dynamics: an official publication of the American Association of Anatomists 2002 224 2 135 143 10.1002/dvdy.10092
30. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Davis JA, Naruse S, Chen H, Eckman C, Younkin S, Price DL, Borchelt DR, Sisodia SS, Wong PC, Neuron 1998 20 3 603 609 10.1016/S0896-6273(00)80998-8 9539132
31. Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates A1-42/43 expression. Qian S, Jiang P, Guan XM, Singh G, Trumbauer ME, Yu H, Chen HY, Van de Ploeg LH, Zheng H, Neuron 1998 20 3 611 617 10.1016/S0896-6273(00)80999-X 9539133
32. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Sasahara M, Fries JW, Raines EW, Gown AM, Westrum LE, Frosch MP, Bonthron DT, Ross R, Collins T, Cell 1991 64 1 217 227 10.1016/0092-8674(91)90223-L 1986868
33. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Kojima N, Wang J, Mansuy IM, Grant SG, Mayford M, Kandel ER, Proc Natl Acad Sci U S A 1997 94 9 4761 4765 10.1073/pnas.94.9.4761 9114065
34. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E, Ashe KH, Am J Pathol 2008 173 3 762 772 10.2353/ajpath.2008. 080175 18669616
35. Persistent amyloidosis following suppression of A production in a transgenic model of Alzheimer's disease. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, et al. PLoS Medicine 2005 2 12 355 10.1371/journal.pmed.0020355 16279840
36. Developmental expression of the CaM kinase II isoforms: ubiquitous - and -CaM kinase II are the early isoforms and most abundant in the developing nervous system. Bayer KU, Lohler J, Schulman H, Harbers K, Brain Res Mol Brain Res 1999 70 1 147 154 10381553
37. Behavioral phenotyping strategies for mutant mice. Crawley JN, Neuron 2008 57 6 809 818 10.1016/j.neuron.2008.03.001 18367082
38. Thigmotaxis as a test for anxiolytic activity in rats. Treit D, Fundytus M, Pharmacol Biochem Behav 1988 31 4 959 962 10.1016/0091-3057(88)90413-3 3252289
39. Medium spiny neurons of the neostriatal matrix exhibit specific, stereotyped changes in dendritic arborization during a critical developmental period in mice. Lee H, Sawatari A, Eur J Neurosci 2011 34 9 1345 1354 10.1111/j.1460-9568.2011.07852.x 21995728
40. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ, Neural Dev 2008 3 15 10.1186/1749-8104-3-15 18573216
41. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, et al. J Neurosci 2005 25 5 1219 1225 10.1523/JNEUROSCI.4660-04.2005 15689559
42. Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. Wang Z, Wang B, Yang L, Guo Q, Aithmitti N, Songyang Z, Zheng H, J Neurosci 2009 29 35 10788 10801 10.1523/JNEUROSCI.2132-09.2009 19726636
43. γ-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, Mitteregger G, Kretzschmar HA, Haass C, Herms J, J Neurosci 2009 29 33 10405 10409 10.1523/JNEUROSCI.2288-09.2009 19692615
44. The Upside of APP at Synapses. Hoe HS, Lee HK, Pak DT, CNS Neurosci Ther 2010 18 1 47 56 21199446
45. Cell-surface -amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ, J Neurosci 1995 15 3 Pt 2 2157 2167 7891158
46. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Lee KJ, Moussa CE, Lee Y, Sung Y, Howell BW, Turner RS, Pak DT, Hoe HS, Neuroscience 2010 169 1 344 356 10.1016/j.neuroscience.2010.04.078 20451588
47. Synaptotrophic effects of human amyloid protein precursors in the cortex of transgenic mice. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR, Brain Res 1994 666 2 151 167 10.1016/0006-8993(94)90767-6 7882025
48. FAD-mutation of APP is associated with a loss of its synaptotrophic activity. Seeger G, Gartner U, Ueberham U, Rohn S, Arendt T, Neurobiol Dis 2009 35 2 258 263 10.1016/j.nbd.2009.05.003 19450683
49. The Drosophila -amyloid precursor protein homolog promotes synapse differentiation at the neuromuscular junction. Torroja L, Packard M, Gorczyca M, White K, Budnik V, J Neurosci 1999 19 18 7793 7803 10479682
50. Dopamine release in prefrontal cortex in response to -amyloid activation of 7 * nicotinic receptors. Wu J, Khan GM, Nichols RA, Brain Res 2007 1182 82 89 17935702
51. Soluble amyloid 1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Trabace L, Kendrick KM, Castrignano S, Colaianna M, De Giorgi A, Schiavone S, Lanni C, Cuomo V, Govoni S, Neuroscience 2007 147 3 652 663 10.1016/j.neuroscience.2007.04.056 17560043
52. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1E9 transgenic mice. Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, Sisodia SS, Mufson EJ, J Neurosci 2005 25 44 10220 10229 10.1523/JNEUROSCI.2773-05.2005 16267229
53. Robust amyloid clearance in a mouse model of AD provides novel insights into the mechanism of A immunotherapy. Wang A, Das P, Switzer RC, Golde TE, Jankowsky JL, J Neurosci 2011 31 11 4124 4136 10.1523/JNEUROSCI.5077-10.2011 21411653
54. Control of memory formation through regulated expression of a CaMKII transgene. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER, Science 1996 274 5293 1678 1683 10.1126/science.274.5293.1678 8939850
55. The Jackson Laboratory handbook on genetically standarized mice The Jackson Laboratory, Bar Harbor, ME, Flurkey K, Currer JM, 6 2009
56. Transgenic calmodulin-dependent protein kinase II activation: dose-dependent effects on synaptic plasticity, learning, and memory. Bejar R, Yasuda R, Krugers H, Hood K, Mayford M, J Neurosci 2002 22 13 5719 5726 12097524
57. Rodent A modulates the solubility and distribution of amyloid deposits in transgenic mice. Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR, J Biol Chem 2007 282 31 22707 22720 10.1074/jbc.M611050200 17556372
58. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE, J Clin Invest 2006 116 1 193 201 16341263
59. Insights into the mechanisms of action of anti-A antibodies in Alzheimer's disease mouse models. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, et al. FASEB J 2006 20 14 2576 2578 10.1096/fj.06-6463fje 17068112
60. Franklin KBJ, Paxinos G, The mouse brain in stereotaxic coordinates Acadmic Press, San Diego, CA 3 2008